 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Penumbra, Inc. (PEN) designs, develops, manufactures, and markets medical devices.
The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; and aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the JET, ACE and 3D Revascularization Device brands.
It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands.
In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand.
Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand.
The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets.
On May 7th, Penumbra (PEN) reported 1st Quarter March 2019 earnings of $0.23 per share on revenue of $128.4 million. The consensus earnings estimate was $0.13 per share.
Shares have formed a bullish "cup and handle" and are expected to move higher from this formation.
Entry Point: $162.00
Stop Loss: $154.00
Trading Range: $110.84 - $170.00
Target Price: $179.00
PEN closed at $177.90
